Suppr超能文献

“告诉朱莉安娜”:在参与 1 期杀微生物剂研究的不同种族、活跃的年轻女性中,候选杀微生物剂 VivaGel®和两种安慰剂凝胶的可接受性。

"Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.

机构信息

HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.

出版信息

AIDS Behav. 2012 Oct;16(7):1761-74. doi: 10.1007/s10461-011-0028-6.

Abstract

This study assessed acceptability of the candidate microbicide VivaGel(®) and two placebo gels among 61 sexually active young US and Puerto Rican women at three sites. Participants were randomly assigned to use one of the gels twice per day for 14 days. At trial completion, 59% of the women in the VivaGel(®) group reported being likely to use the gel in the future, whereas 23% were unlikely to use it and 18% were undecided. Participants reported problems with all three gels, including the "universal" placebo containing hydroxyethyl cellulose (HEC). The most frequent complaints were leakage, interference with sexual behavior, and decreased sexual satisfaction. Some of the complaints are not new but remain unresolved. Women's perceived risk of HIV infection may determine whether the gels are used. Users also may want a choice of viscosity. Poor acceptability of vaginal microbicide formulations may result in poor adherence to gel use during efficacy trials and compromise validity of results.

摘要

本研究评估了候选杀微生物剂 VivaGel(®)和两种安慰剂凝胶在三个地点的 61 名活跃的美国和波多黎各年轻女性中的可接受性。参与者被随机分配每天使用其中一种凝胶两次,持续 14 天。在试验结束时,VivaGel(®)组中有 59%的女性表示将来可能会使用该凝胶,而 23%的女性表示不太可能使用,18%的女性表示不确定。参与者报告了所有三种凝胶的问题,包括含有羟乙基纤维素 (HEC)的“通用”安慰剂。最常见的抱怨是泄漏、性行为干扰和性满意度下降。其中一些抱怨并不是新的,但仍未得到解决。女性对 HIV 感染的感知风险可能决定她们是否使用这些凝胶。使用者可能还希望选择不同的黏度。阴道杀微生物剂配方的可接受性差可能导致在疗效试验中对凝胶使用的依从性差,并影响结果的有效性。

相似文献

3
Young women's experience with using videoconferencing for the assessment of sexual behavior and microbicide use.
Telemed J E Health. 2013 Nov;19(11):866-71. doi: 10.1089/tmj.2013.0008. Epub 2013 Sep 19.
4
Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.
Cult Health Sex. 2012;14(2):151-66. doi: 10.1080/13691058.2011.630099. Epub 2011 Nov 15.
6
User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
Arch Sex Behav. 2014 Oct;43(7):1459-67. doi: 10.1007/s10508-013-0235-5. Epub 2014 Jan 23.
10
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.

引用本文的文献

1
Dendrimer-Mediated Delivery of DNA and RNA Vaccines.
Pharmaceutics. 2023 Mar 30;15(4):1106. doi: 10.3390/pharmaceutics15041106.
2
Dendrimers, an Emerging Opportunity in Personalized Medicine?
J Pers Med. 2022 Aug 19;12(8):1334. doi: 10.3390/jpm12081334.
3
Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
PLoS One. 2022 Feb 22;17(2):e0263664. doi: 10.1371/journal.pone.0263664. eCollection 2022.
4
Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1774. doi: 10.1002/wnan.1774. Epub 2022 Jan 12.

本文引用的文献

2
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
3
Unprotected anal intercourse and sexually transmitted diseases in high-risk heterosexual women.
Am J Public Health. 2011 Apr;101(4):745-50. doi: 10.2105/AJPH.2009.181883. Epub 2010 Jun 17.
4
Efficacy dilution in randomized placebo-controlled vaginal microbicide trials.
Emerg Themes Epidemiol. 2009 Oct 9;6:5. doi: 10.1186/1742-7622-6-5.
5
Women's experiences with anal sex: motivations and implications for STD prevention.
Perspect Sex Reprod Health. 2009 Sep;41(3):142-9. doi: 10.1363/4114209.
6
Microbicide acceptability research: recent findings and evolution across phases of product development.
Curr Opin HIV AIDS. 2008 Sep;3(5):581-6. doi: 10.1097/COH.0b013e32830aba00.
7
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.
8
Assessing microbicide acceptability: a comprehensive and integrated approach.
AIDS Behav. 2008 Mar;12(2):272-83. doi: 10.1007/s10461-007-9266-z. Epub 2007 Jun 26.
9
Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.
AIDS Care. 2007 Jul;19(6):817-21. doi: 10.1080/09540120601133576.
10
Acceptability of Carraguard vaginal gel use among Thai couples.
AIDS. 2006 Nov 14;20(17):2141-8. doi: 10.1097/QAD.0b013e32801086c9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验